Table 3.
Subgroup analysis of the role of CCAT2 in LNM in different types of cancer
| Subgroup | No. of studies | No. of patients | Test of Relationship | Test of Heterogeneity | ||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | Q value | P bias | I2, % | ||||
| Overall | 6 | 691 | 3.09 (1.53-6.26) | <0.01 | 15.68 | 0.005 | 70 | |
| Sample size | ||||||||
| < 100 | 3 | 229 | 1.91 (0.38-9.57) | 0.43 | 8.03 | 0.02 | 75 | |
| ≥ 100 | 3 | 462 | 3.77 (1.57-9.05) | <0.01 | 8.72 | 0.01 | 77 | |
| Tumor type | ||||||||
| Digestive system | 2 | 312 | 3.37 (0.87-13.11) | 0.08 | 5.95 | 0.01 | 83 | |
| Urinary system | 2 | 144 | 1.02 (0.36-2.92) | 0.97 | 0.96 | 0.33 | 0 | |
| Others | 2 | 235 | 5.89 (3.26-10.64) | <0.01 | 0.05 | 0.82 | 0 | |
| Reference control | ||||||||
| GAPDH | 5 | 464 | 3.66 (1.67-8.03) | <0.01 | 10.35 | 0.03 | 61 | |
| RNU6B | 1 | 227 | 1.80 (1.06-3.04) | 0.03 | - | - | - | |
| RNA extraction | ||||||||
| TRIzol | 4 | 352 | 2.88 (1.01-8.22) | <0.05 | 9.39 | 0.02 | 68 | |
| Others | 2 | 339 | 3.22 (0.94-11.01) | 0.06 | 6.09 | 0.01 | 84 | |
LNM, lymph node metastasis; OR, odds ratio; 95%CI, 95% confidence interval.